This Idelvion market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth observed during the historical period can be attributed to factors such as the increased adoption of extended half-life therapies, advancements in gene therapy research, greater government healthcare funding, expanding clinical trial data, and the rise in both public and private insurance coverage.
Market growth during the forecast period is driven by increased healthcare investments, higher demand for long-acting therapies, a growing number of hemophilia treatment centers, expanding government incentives, and a greater need for home care services. Key trends in the forecast period include technological innovations, gene therapy, personalized medicine, combination therapies, and the integration of digital health tools.
The increasing incidence of hemophilia B is expected to drive the growth of the idelvion market. Hemophilia B is a genetic bleeding disorder caused by a deficiency in clotting factor IX, resulting in excessive bleeding. The rising number of hemophilia B cases can be attributed to improved diagnosis, increased awareness, better healthcare access, advancements in genetic testing, and longer life expectancy, all of which contribute to more cases being identified and treated. Idelvion is an important treatment option for hemophilia B, offering a more convenient, effective, and sustainable solution to meet the growing patient population's needs. For example, in June 2022, the National Blood Authority in Australia reported an 11.8% increase in the demand for factor IX products in 2021-22 compared to the previous year. Therefore, the rising incidence of hemophilia B is fueling the growth of the idelvion market.
The growing emphasis on personalized medicine is expected to propel the idelvion market. Personalized medicine involves tailoring treatments based on an individual’s unique characteristics, preferences, and genetic profile. This approach is gaining momentum due to advancements in genomics and data analytics, enabling more precise treatments. Personalized medicine is positively impacting Idelvion by supporting customized treatment plans for hemophilia B patients, optimizing dosing, and improving therapeutic outcomes. For example, in February 2024, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration approved 16 novel personalized therapies for rare diseases in 2023, up from six in 2022. As a result, the growing focus on personalized medicine is driving the idelvion market’s growth.
Healthcare infrastructure improvements are expected to stimulate the growth of the idelvion market. Healthcare infrastructure includes essential facilities, resources, and systems required to deliver healthcare services, such as hospitals, clinics, medical equipment, and trained personnel. Enhancing healthcare infrastructure is crucial for improving care quality, increasing accessibility, supporting efficient service delivery, and accommodating growing populations while incorporating advanced medical technologies. Strong healthcare infrastructure ensures the availability and proper use of Idelvion, a recombinant clotting factor IX for hemophilia B treatment. For instance, in May 2023, the UK government confirmed a £20 billion investment in the New Hospital Programme, which aims to build 40 new hospitals in England by 2030. Therefore, improvements in healthcare infrastructure are contributing to the growth of the idelvion market.
The key company operating in the idelvion market is CSL Behring.
North America was the largest region in the idelvion market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in idelvion report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Idelvion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Idelvion (albutrepenonacog alfa) is a recombinant factor IX replacement therapy with an extended half-life, designed to treat and prevent bleeding episodes in individuals with hemophilia B. This treatment provides prolonged clotting factor activity, minimizing the need for frequent infusions, offering more convenience, and enhancing patients' quality of life. Idelvion aids in controlling bleeding and reducing the risk of joint damage for those with hemophilia B, a genetic disorder caused by a deficiency in clotting factor IX.
Idelvion is primarily indicated for hemophilia B, both for prophylactic treatment and on-demand use. Hemophilia B is a genetic condition in which the blood fails to clot properly due to a lack of factor IX. It is suitable for use in pediatric, adult, and geriatric patients and is available through hospitals, specialty clinics, home healthcare providers, and retail pharmacies.
The idelvion market research report is one of a series of new reports that provides idelvion market statistics, including idelvion industry global market size, regional shares, competitors with a idelvion market share, detailed idelvion market segments, market trends and opportunities, and any further data you may need to thrive in the idelvion industry. This idelvion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The idelvion market consists of sales of prothrombin complex concentrate, immune globulin subcutaneous, and factor XIII products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth observed during the historical period can be attributed to factors such as the increased adoption of extended half-life therapies, advancements in gene therapy research, greater government healthcare funding, expanding clinical trial data, and the rise in both public and private insurance coverage.
Market growth during the forecast period is driven by increased healthcare investments, higher demand for long-acting therapies, a growing number of hemophilia treatment centers, expanding government incentives, and a greater need for home care services. Key trends in the forecast period include technological innovations, gene therapy, personalized medicine, combination therapies, and the integration of digital health tools.
The increasing incidence of hemophilia B is expected to drive the growth of the idelvion market. Hemophilia B is a genetic bleeding disorder caused by a deficiency in clotting factor IX, resulting in excessive bleeding. The rising number of hemophilia B cases can be attributed to improved diagnosis, increased awareness, better healthcare access, advancements in genetic testing, and longer life expectancy, all of which contribute to more cases being identified and treated. Idelvion is an important treatment option for hemophilia B, offering a more convenient, effective, and sustainable solution to meet the growing patient population's needs. For example, in June 2022, the National Blood Authority in Australia reported an 11.8% increase in the demand for factor IX products in 2021-22 compared to the previous year. Therefore, the rising incidence of hemophilia B is fueling the growth of the idelvion market.
The growing emphasis on personalized medicine is expected to propel the idelvion market. Personalized medicine involves tailoring treatments based on an individual’s unique characteristics, preferences, and genetic profile. This approach is gaining momentum due to advancements in genomics and data analytics, enabling more precise treatments. Personalized medicine is positively impacting Idelvion by supporting customized treatment plans for hemophilia B patients, optimizing dosing, and improving therapeutic outcomes. For example, in February 2024, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration approved 16 novel personalized therapies for rare diseases in 2023, up from six in 2022. As a result, the growing focus on personalized medicine is driving the idelvion market’s growth.
Healthcare infrastructure improvements are expected to stimulate the growth of the idelvion market. Healthcare infrastructure includes essential facilities, resources, and systems required to deliver healthcare services, such as hospitals, clinics, medical equipment, and trained personnel. Enhancing healthcare infrastructure is crucial for improving care quality, increasing accessibility, supporting efficient service delivery, and accommodating growing populations while incorporating advanced medical technologies. Strong healthcare infrastructure ensures the availability and proper use of Idelvion, a recombinant clotting factor IX for hemophilia B treatment. For instance, in May 2023, the UK government confirmed a £20 billion investment in the New Hospital Programme, which aims to build 40 new hospitals in England by 2030. Therefore, improvements in healthcare infrastructure are contributing to the growth of the idelvion market.
The key company operating in the idelvion market is CSL Behring.
North America was the largest region in the idelvion market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in idelvion report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Idelvion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Idelvion (albutrepenonacog alfa) is a recombinant factor IX replacement therapy with an extended half-life, designed to treat and prevent bleeding episodes in individuals with hemophilia B. This treatment provides prolonged clotting factor activity, minimizing the need for frequent infusions, offering more convenience, and enhancing patients' quality of life. Idelvion aids in controlling bleeding and reducing the risk of joint damage for those with hemophilia B, a genetic disorder caused by a deficiency in clotting factor IX.
Idelvion is primarily indicated for hemophilia B, both for prophylactic treatment and on-demand use. Hemophilia B is a genetic condition in which the blood fails to clot properly due to a lack of factor IX. It is suitable for use in pediatric, adult, and geriatric patients and is available through hospitals, specialty clinics, home healthcare providers, and retail pharmacies.
The idelvion market research report is one of a series of new reports that provides idelvion market statistics, including idelvion industry global market size, regional shares, competitors with a idelvion market share, detailed idelvion market segments, market trends and opportunities, and any further data you may need to thrive in the idelvion industry. This idelvion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The idelvion market consists of sales of prothrombin complex concentrate, immune globulin subcutaneous, and factor XIII products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Idelvion Market Characteristics4. Idelvion Market Trends and Strategies5. Idelvion Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Idelvion Pricing Analysis & Forecasts30. Global Idelvion Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Idelvion Market32. Recent Developments in the Idelvion Market
3. Idelvion Market Biologic Drug Characteristics
6. Global Idelvion Growth Analysis and Strategic Analysis Framework
8. Idelvion Market Segmentation
9. Global Idelvion Epidemiology of Clinical Indications
10. Idelvion Market Regional and Country Analysis
11. Asia-Pacific Idelvion Market
12. China Idelvion Market
13. India Idelvion Market
14. Japan Idelvion Market
15. Australia Idelvion Market
16. South Korea Idelvion Market
17. Western Europe Idelvion Market
18. UK Idelvion Market
19. Germany Idelvion Market
20. France Idelvion Market
21. Eastern Europe Idelvion Market
22. North America Idelvion Market
23. USA Idelvion Market
24. Canada Idelvion Market
25. South America Idelvion Market
26. Middle East Idelvion Market
27. Africa Idelvion Market
28. Idelvion Market Competitive Landscape and Company Profiles
29. Global Idelvion Market Pipeline Analysis
33. Idelvion Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Idelvion Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on idelvion market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for idelvion? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The idelvion market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Hemophilia B; Prophylactic Treatment; on-Demand Treatment2) by Patient Age Group: Pediatrics; Adults; Geriatrics
3) by Distribution Channel: Hospitals; Specialty Clinics; Home Healthcare Providers; Retail Pharmacies
Key Companies Mentioned: CSL Behring
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- CSL Behring
